|Bid||84.12 x 1100|
|Ask||90.00 x 900|
|Day's Range||81.73 - 86.42|
|52 Week Range||57.24 - 127.80|
|Beta (5Y Monthly)||1.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 04, 2021 - Feb 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jul 02, 2010|
|1y Target Est||181.67|
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces clinical and regulatory progress by multiple partners utilizing antibodies from its OmniAb® discovery platform. Two large multinational pharmaceutical companies with a license to OmniAb have reached clinical-development milestones with their programs. The progress by these companies resulted in a total of $4.5 million in milestone payments being earned by Ligand.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration (FDA) for SESQUIENT, a Captisol-enabled™ Fosphenytoin (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients.
Ligand (LGND) reports lower-than-expected third-quarter 2020 earnings and revenues. Outlook for 2020 & 2021 also are below expectations. Stock down.